Drugs / Ganaplacide
Ganaplacide
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05330273 | Apr → Nov 2022 | malaria | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT05236530 | Mar → Oct 2022 | malaria | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT05084651 | Nov 2021 → May 2022 | malaria | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT04072302 | Sep 2014 → Nov 2017 | malaria | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 24 trials · 2 met primary | ||||||
| Phase 2 | NCT07235033 | Jan 2024 → Mar 2025 | Plasmodium falciparum malaria | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT04546633 | Feb 2021 → Aug 2024 | Plasmodium falciparum malaria | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT03167242 | Aug 2017 → Jun 2021 | Plasmodium falciparum malaria | Novartis Pharmaceuticals | Completed | Mixed |
| Phase 2 | NCT01753323 | Mar 2013 → Aug 2014 | malaria | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT05842954 | Mar 2024 → Jun 2025 | Plasmodium falciparum malaria | Novartis Pharmaceuticals | Completed | Met primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-11-12 | Novartis Pharmaceuticals | Results Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance novartis.com ↗
Novartis today announced positive results from KALUMA, a Phase III study for new malaria treatment KLU156 (ganaplacide/lumefantrine, or GanLum). |
| 2021-09-29 | Novartis Pharmaceuticals | Results Novartis and Medicines for Malaria Venture report positive results for Phase 2b study of novel ganaplacide/lumefantrine combination in children with malaria novartis.com ↗
The ganaplacide/lumefantrine solid dispersion formulation combination met the primary objective in Part B of the study in children with acute uncomplicated malaria. |
| 2016-09-21 | Novartis Pharmaceuticals | Results Novel Novartis malaria compound shows potential to be effective against infections resistant to all currently available antimalarial drugs novartis.com ↗
Today Novartis published proof of concept study results in the New England Journal of Medicine showing that its new antimalarial compound, KAF156, demonstrated activity against both vivax and falciparum malaria, including artemisinin-resistant parasites. |
All press releases naming this drug 7 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ganaplacide | “Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group,...” PMID 37327809 ↗ Jun 20235“KLU156, a fixed dose combination of ganaplacide (KAF156) and a solid dispersion formulation of lumefantrine (lumefantrine-SDF)” NCT05842954 ↗ “ganaplacide + lumefantrine solid dispersion formulation” NCT07235033 ↗ |
| Known as | Ganaplacida | ChEMBL registry synonym — accepted as the source's own label CHEMBL2058833 ↗ |
| Known as | GNF 156 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2058833 ↗ |
| Known as | KAF156 | “KLU156, a fixed dose combination of ganaplacide (KAF156) and a solid dispersion formulation of lumefantrine (lumefantrine-SDF)” NCT05842954 ↗ |
| Modality | Small molecule | “KAF156 belongs to a new class of antimalarial agents (imidazolopiperazines)” PMID 27653565 ↗ Sep 2016 |
| Route | Oral | “supplied as tablets for oral use” NCT01753323 ↗ |